Skip to main content
SpringerLink
Log in

Expand the treatment horizon of premenstrual dysphoric disorder with targeted therapeutic approaches

  • Practical Issues and Updates
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Premenstrual dysphoric disorder (PMDD) is a sex-specific cyclic mood disorder characterized by heterogenous mood and physical symptoms during the luteal phase of the menstrual cycle. Currently available treatment options for PMDD are limited and suboptimal. With advanced understanding in pathophysiology of PMDD, the interaction between the gamma-aminobutyric acid (GABA) system and allopregnanolone, a neuroactive steroid derivative of progesterone, have been proposed as a potentially effective target for the treatment of PMDD. Although further research is needed, early clinical findings of new targeted treatments, such as dutasteride, isoallopregnanolone and ulipristal acetate, have demonstrated promising results in women with PMDD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sikes-Keilp C, Rubinow DR. GABA-ergic modulators: new therapeutic approaches to premenstrual dysphoric disorder. CNS Drugs. 2023;37(8):679–93.

    Article  CAS  PubMed  Google Scholar 

  2. Tiranini L, Nappi RE. Recent advances in understanding/management of premenstrual dysphoric disorder/premenstrual syndrome. Fac Rev. 2022;11:11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Hantsoo L, Payne JL. Towards understanding the biology of premenstrual dysphoric disorder: from genes to GABA. Neurosci Biobehav Rev. 2023;149: 105168.

    Article  CAS  PubMed  Google Scholar 

  4. Sundström-Poromaa I, Comasco E. New pharmacological approaches to the management of premenstrual dysphoric disorder. CNS Drugs. 2023;37(5):371–9.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Steiner M, Ravindran AV, LeMelledo JM, et al. Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women. J Clin Psychiatry. 2008;69(6):991–8.

    Article  CAS  PubMed  Google Scholar 

  6. Kornstein SG, Pearlstein TB, Fayyad R, et al. Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies. J Clin Psychiatry. 2006;67(10):1624–32.

    Article  CAS  PubMed  Google Scholar 

  7. Yonkers KA, Kornstein SG, Gueorguieva R, et al. Symptom-onset dosing of sertraline for the treatment of premenstrual dysphoric disorder: a randomized clinical trial. JAMA Psychiat. 2015;72(10):1037–44.

    Article  Google Scholar 

  8. de Wit AE, de Vries YA, de Boer MK, et al. Efficacy of combined oral contraceptives for depressive symptoms and overall symptomatology in premenstrual syndrome: pairwise and network meta-analysis of randomized trials. Am J Obstet Gynecol. 2021;225(6):624–33.

    Article  PubMed  Google Scholar 

  9. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2012;2:CD006586.

    Google Scholar 

  10. Martinez PE, Rubinow DR, Nieman LK, et al. 5α-reductase inhibition prevents the luteal phase increase in plasma allopregnanolone levels and mitigates symptoms in women with premenstrual dysphoric disorder. Neuropsychopharmacology. 2016;41(4):1093–102.

    Article  CAS  PubMed  Google Scholar 

  11. Bixo M, Ekberg K, Poromaa IS, et al. Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist sepranolone (UC1010)-A randomized controlled trial. Psychoneuroendocrinology. 2017;80:46.

    Article  CAS  PubMed  Google Scholar 

  12. Bäckström T, Ekberg K, Hirschberg AL, et al. A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder. Psychoneuroendocrinology. 2021;133: 105426.

    Article  PubMed  Google Scholar 

  13. Comasco E, Kopp Kallner H, Bixo M, et al. Ulipristal acetate for treatment of premenstrual dysphoric disorder: a proof-of-concept randomized controlled trial. Am J Psychiatry. 2021;178:256.

    Article  PubMed  Google Scholar 

  14. Kaltsouni E, Fisher PM, Dubol M, et al. Brain reactivity during aggressive response in women with premenstrual dysphoric disorder treated with a selective progesterone receptor modulator. Neuropsychopharmacology. 2021;46(8):1460–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Young-A Heo

Authors
  1. Young-A Heo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Young-A Heo.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

Young-A Heo, a salaried employee of Adis International Ltd/Springer Nature and an editor of Drugs & Therapy Perspectives, was not involved in any publishing decisions for the manuscript and declares no declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability

Not applicable.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heo, YA. Expand the treatment horizon of premenstrual dysphoric disorder with targeted therapeutic approaches. Drugs Ther Perspect 40, 27–30 (2024). https://doi.org/10.1007/s40267-024-01046-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-024-01046-z

Search

Navigation